Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005)

Journal of the American Veterinary Medical Association

Volumn 230, Issue 12, 2007, Pages 1877-1881

  Barnard, Sandra M ^a   Zuber, R Max ^a   Moore, Antony S ^b  

^a Gladesville Veterinary Hospital   (Australia)

^b Veterinary Oncology Consultants   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE TUMOR; DOG; DOG DISEASE; FEMALE; MALE; METHODOLOGY; PAIN; PALLIATIVE THERAPY; RETROSPECTIVE STUDY; SURVIVAL; TIME; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; ANIMALS; BONE NEOPLASMS; DOG DISEASES; DOGS; FEMALE; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 34250362747     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.230.12.1877     Document Type: Article

References (13)

1. Moore AS, Ogilvie GK. Tumors of bone. In: Ogilvie GK, Moore AS, eds. Managing the canine cancer patient. Yardley, Pa: Veterinary Learning Systems, 2006;565-589.
2. Kent MS, Strom A, London CA, et al. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. J Vet Intern Med 2004;18:540-544.
3. Green EM, Adams WM, Forest LJ. Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc 2002;38:445-451.
4. McEntee MC, Page RL, Novotney CA, et al. Palliative radiotherapy for canine appendicular osteosarcoma. Vet Radiol Ultrasound 1993;34:367-370.
5. Ramirez O, Dodge RK, Page RL, et al. Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Vet Radiol Ultrasound 1999;40:517-522.
6. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6:392-400.
7. Silberstein E. Teletherapy and radiopharmaceutical therapy and painful bone metastases. Semin Nucl Med 2005;35:152-158.
8. Lattimer JC, Corwin LA, Stapleton J, et al. Clinical and clincopathological response of canine bone tumor patients to treatment with Samarium-153-EDTMP. J Nucl Med 1990;31:1316-1325.
9. Milner RJ, Dormehl I, Louw WKA, et al. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours. J South Afr Vet Assoc 1998;69:12-17.
10. Aas M, Moe L, Gamlem H, et al. Internal radionuclide therapy of primary osteosarcoma in dogs using 153 Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP). Clin Cancer Res 1999;5(suppl 10):3148s-3152s.
11. Veterinary Co-operative Oncology Group. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats vl.0. Vet Comp Oncol 2004;2:195-213.
12. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-999.
13. Brown EM, Ruslander DM, Azuma C, et al. A feasibility study of low dose total body irradiation for relapsed canine lymphoma. Vet Comp Oncol 2006;4:75-83.